Duloxetine
Product Images NDC 0904-7045

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 0904-7045). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

530e2d92 592c 488e 9a3b 1a61f09e6fc1 00

530e2d92 592c 488e 9a3b 1a61f09e6fc1 00
This is a description of a medication called Duloxetine delayed-release capsules, which is only available by prescription. The medication comes in a 100-capsule package and is distributed by the company MAJOR. The National Drug Code (NDC) for the medication is 0904-7044-61 and it comes with a medication guide that should be dispensed by the pharmacist. The dosage and other important information about the medication can be found on the package insert.*
FDA Label Image

530e2d92 592c 488e 9a3b 1a61f09e6fc1 01

530e2d92 592c 488e 9a3b 1a61f09e6fc1 01
This is a description of a medication called Duloxetine. It comes in delayed-release capsules with NDC code 0904-7043-61 and is to be dispensed with a medication guide. It is only available with a prescription and there are 100 capsules per unit dose. The manufacturer is called Major and the address is included as 7N Caur Pk. St 353, Uvonts i 43183 USA.*
FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)
FDA Label Image

Figure-2 (Duloxetine Fig2)

Figure-2 (Duloxetine Fig2)
FDA Label Image

Figure-3 (Duloxetine Fig3)

Figure-3 (Duloxetine Fig3)
FDA Label Image

Figure 4: Percentage Of Dpnp Adult Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Dpnp-2) (Duloxetine Fig4)

Figure 4: Percentage Of Dpnp Adult Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Dpnp-2) (Duloxetine Fig4)
This is a graph showing the percentage of patients who improved in pain when taking Duloxetine (60mg BID, 60mg QD) or Placebo. The X-axis represents the percentage improvement in pain from baseline and the Y-axis represents the percentage of patients improved. The graph shows that more patients improved when taking Duloxetine compared to Placebo.*
FDA Label Image

Figure 5 (Duloxetine Fig5)

Figure 5 (Duloxetine Fig5)
The text describes a graph showing the percentage of patients who have shown improvement in pain and their level of improvement after taking various medications. There are three medication options: Duloxetine 60 mg twice a day, Duloxetine 60 mg once a day, and a placebo. The X-axis shows the percent improvement in pain from baseline (starting point). The Y-axis shows the percentage of patients who have improved. The graph shows that a higher percentage of patients have improved with Duloxetine compared to the placebo. However, more patients have shown improvement with Duloxetine twice daily compared to once daily. The graph also has multiple markings for improvement levels above 10%, with the highest level being over 80%.*
FDA Label Image

Figure 6 (Duloxetine Fig6)

Figure 6 (Duloxetine Fig6)
This appears to be a table displaying the percent of patients who have improved with different doses of duloxetine (20mg, 60mg, and 120mg) compared to a placebo for pain relief. The numbers on the bottom represent the percent improvement in pain from baseline, ranging from 0 to 100.*
FDA Label Image

Figure 7 (Duloxetine Fig7)

Figure 7 (Duloxetine Fig7)
This is a chart showing the percentage of patients improved with either a Placebo or Duloxetine (at doses of 60/120mg) once. The chart also displays percent improvement in pain from Baseline (BOCF).*
FDA Label Image

Figure 8 (Duloxetine Fig8)

Figure 8 (Duloxetine Fig8)
The text provides a graph showing the percentage of patients improved with placebo and duloxetine medication taken once daily. The X-axis indicates the percent improvement in pain from baseline, and the Y-axis indicates the number of patients. However, there is not enough context to determine the nature of the study or the medical condition under consideration.*
FDA Label Image

Figure 10: Percentage Of Adult Patients With Oa Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Oa-1) (Duloxetine Fig9)

Figure 10: Percentage Of Adult Patients With Oa Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Oa-1) (Duloxetine Fig9)
FDA Label Image

Chemical Structure (Duloxetine Str)

Chemical Structure (Duloxetine Str)
FDA Label Image

Carton Label (Image 02)

Carton Label (Image 02)
This is a description of Duloxetine delayed-release capsules USP manufactured by Major Pharmaceuticals. The NDC number is 0904-7045-61, and each unit dose contains 100 capsules. These capsules should be dispensed by a pharmacist with a medication guide. The dosage is 30-60mg per day, depending on the patient's condition. The medication is indicated for Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Diabetic Peripheral Neuropathic Pain (DPNP), and Fibromyalgia (FM). The text also includes instructions for storage, and a lot number and expiration date for the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.